Openbookopenbook
Equity
CTMX
+0.0 · +0.00%
USD · NASDAQ

CytomX Therapeutics Inc(CTMX) Stock Analysis | Healthcare

USD --+0.00%
Reward39Moderate
Risk72High
75%Data
Revenue down 92% YoY
Earnings Deterioration
Market Cap:714.71M
ⓘ
Reward Rating
39
Moderate
Reward Assessment
75% data coverage
Bottom 5% of stocksView factors
ⓘ
Risk Rating
72
High
Risk Assessment
5 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CTMX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for CTMX, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $12.25.

What is CytomX Therapeutics Inc?

operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.

CTMX · Verdict

Limited reward · high risk

CTMX's standout is balance sheet; volatility and cash flow weigh on the picture.

Based on 88% data coverage

CTMX · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet86/100

    Current ratio 3.09

Watchouts 5

  • Volatility5/100

    Weak vs peers

  • Cash flow29/100

    -99% free-cash-flow margin

  • Valuation31/100

    P/E 14.2×

  • Profitability32/100

    -23% net margin · -38% ROE

  • Growth38/100

    Rev +12.8% CAGR · earnings -43.7%

Model-based scoring. For information only — not financial advice.

What is CytomX Therapeutics Inc?

operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 714.71M.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (39)

The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

ATXSSmall Cap / 718M market cap
Astria Therapeutics Inc
Compare
OCSSmall Cap / 719M market cap
Oculis Holding AG Ordinary shares
Compare
RGNXSmall Cap / 711M market cap
Regenxbio Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap714.71M
P/E RatioN/A
Dividend YieldN/A
Beta2.138
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
4191,063 shares
$1.2M
0
6-9months
0
0
9-12months
0
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.